GeneriCo has assembled a team of exceptionally talented and experienced leaders and scientists to advance the Mission: To create a unique environment of collaboration to develop specialty generic drugs with uncompromising quality, value and speed to market; creating a positive impact on the quality of people’s lives.

The Saint Louis based team includes industry experts (over 125 cumulative years) with consistent success in pharmaceuticals and generics. The team is committed to bring difficult to make generic drugs to the US market, and beyond.


Dan Thompson, MS, JD.


Dan Thompson possesses a dynamic range of skills and leadership experiences including sales and marketing, legal, broad business and operation expertise spanning both branded and generic pharmaceuticals. An experienced leader with over 25 years in the healthcare and pharmaceutical industry (branded and generic), Dan has led numerous due diligence assessments and negotiated complex agreements in the US, EU and Asia-Pacific markets that have increased revenue and profits. Dan has also lead distressed organizations through Consent Decree initiatives with the FDA and successfully exited following a bankruptcy process. Dan’s broad-based experience in commercialization leading Legal, Business Development and Quality, Medical Affairs, Compliance and Operations, form the backbone of his leadership role as President and Chief Executive Officer with GeneriCo. Dan holds a JD from St. Louis University School of Law with a Certificate in Health Law and an MS from the University of Missouri in Molecular Biology. Dan has mentored new start-up executives at the Washington University Skandalaris Center and has served as an Adjunct Professor at St. Louis College of Pharmacy.

Rod Novak, MS, CPA


As Chief Administrative Officer for GeneriCo, Rod is a key member of the management team leading all administrative functions including Strategic and Business Planning, Corporate Financial and Budgetary Management, Information Technology and Data Management, Corporate Operations Support, Product Forecasting and Analysis, Product Logistics and Distribution, Project Management and Process Improvement. He is an experienced corporate and commercial leader with over 32 years of experience in the pharmaceutical industry. Within large (DuPont Pharmaceuticals) and Specialty Pharmaceutical (KV and Covidien/Mallinckrodt), Rod brings functional expertise in the areas of business planning and execution, finance and accounting, forecasting and analysis, acquisitions and divestures, sales and operations planning (S&OP), sales, marketing, sales and marketing operations, Lean Six Sigma/process improvement and project management. Rod holds a BS and Masters of Management Science from Northern Illinois University as well as a CPA from The University of Illinois.

Elio Mariani, Ph.D.


Elio is an industry veteran and brings over 40 years of executive experience in pharmaceutical research and development as GeneriCo’s Chief Scientific Advisor. His depth of experience and expertise includes development and commercialization of over 150 products in ANDA and NDA applications. Elio’s skill set is broad; dosage form development, clinical affairs, analytical chemistry, regulatory affairs, intellectual property, drug delivery systems and pharmaceutical processes. Elio has contributed impact with KV Pharmaceuticals, Hercon, Akzo, Sterling Winthrop Drug and Bristol Meyers Squibb. Elio received his PhD from the Massachusetts College of Pharmacy and Health Sciences.

Mike Grimshaw, Ph.D.


A recognized global expert in drug delivery, Mike Grimshaw has 40 years of expertise that he brings to GeneriCo as a Founder and SVP Formulation & Manufacturing. Mike’s leadership roles have included formulation of 22 generic drugs that have been approved and launched, as well as expertise in developing difficult to formulate modified release dosage forms. Mike was part of FMC’s founding management team. Under this guidance, grew FMC into a global business. His expertise, and leadership with FMC, and was critical to the success of the specialty pharmaceutical company, KV Pharmaceutical. Mike holds 2 patents with 3 pending, for new drug delivery technologies. Mike received his PhD from Queen’s University, Northern Ireland.